NBIX
HEALTHCARENeurocrine Biosciences Inc
AI Insight
What's Moving NBIX Today?
No stock-specific AI insight has been generated for NBIX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$122.14$169.57
$161.44
Fundamentals
Market Cap$16.3B
P/E Ratio24.9
EPS$6.49
Dividend Yield—
Dividend / Share—
ROE22.5%
Profit Margin21.5%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding100.5M
NBIX News
33 articles- New Strong Buy Stocks for June 24thYahoo Finance·Jun 24, 2026
- Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal PeriodYahoo Finance·Jun 15, 2026
- Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITYStreetInsider·Jun 15, 2026
- Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026Yahoo Finance·Jun 15, 2026
- Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?Yahoo Finance·Jun 15, 2026
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026Yahoo Finance·Jun 15, 2026
- Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026Yahoo Finance·Jun 15, 2026
- How New INGREZZA TD Data in Underserved Patients Could Shape Neurocrine Biosciences’ (NBIX) Investment StorySimply Wall Street·Jun 14, 2026
- Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals24-7 Press Release Newswire·Jun 12, 2026
- Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of PatientsYahoo Finance·Jun 8, 2026
- Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental DisabilitiesYahoo Finance·Jun 8, 2026
- Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price MomentumYahoo Finance·Jun 5, 2026
- RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)Yahoo Finance·Jun 4, 2026
- A Look At Neurocrine Biosciences (NBIX) Valuation As New CRENESSITY Data Heads To ENDO 2026Simply Wall Street·Jun 4, 2026
- Dow Jones Futures Rise, But Broadcom, CrowdStrike, Ciena Hit Techs; SpaceX IPO Price Target SetYahoo Finance·Jun 4, 2026
- Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026Yahoo Finance·Jun 3, 2026
- Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst callsYahoo Finance·Jun 2, 2026
- Centene, Deckers and 14 Other ‘Dividend Hopefuls’Yahoo Finance·Jun 2, 2026
- Neurocrine (NASDAQ: NBIX) grants options and RSUs to directorStock Titan·May 30, 2026
- [Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading ActivityStock Titan·May 30, 2026
- Neurocrine (NASDAQ: NBIX) CSO exercises options, sells 11,000 pre-planned sharesStock Titan·May 30, 2026
- Neurocrine Biosciences (NBIX) director receives 2,567 restricted stock unitsStock Titan·May 30, 2026
- Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC SaysYahoo Finance·May 29, 2026
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in JuneYahoo Finance·May 26, 2026
- US High Growth Tech Stocks To Watch NowYahoo Finance·May 26, 2026
- Bernstein Initiates Coverage of Neurocrine Biosciences (NBIX) with OutperformYahoo Finance·May 25, 2026
- Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) NarrativeYahoo Finance·May 21, 2026
- A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains AttentionYahoo Finance·May 21, 2026
- Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market positionAD HOC NEWS·May 14, 2026
- Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026GlobeNewswire Inc.·May 1, 2026
- Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with SchizophreniaGlobeNewswire Inc.·Apr 12, 2026
- Why Soleno Therapeutics Stock Rocketed Higher on MondayThe Motley Fool·Apr 6, 2026
- Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketBenzinga·Apr 6, 2026
All 33 articles loaded
Price Data
Open$161.62
Previous Close$161.44
Day High$163.53
Day Low$160.42
52 Week High$169.57
52 Week Low$122.14
52-Week Range
$122.14$169.57
$161.44
Fundamentals
Market Cap$16.3B
P/E Ratio24.9
EPS$6.49
Dividend Yield—
Dividend / Share—
ROE22.5%
Profit Margin21.5%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding100.5M
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—